206 related articles for article (PubMed ID: 28108509)
1. Differential PI3Kδ Signaling in CD4
Ahmad S; Abu-Eid R; Shrimali R; Webb M; Verma V; Doroodchi A; Berrong Z; Samara R; Rodriguez PC; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Apr; 77(8):1892-1904. PubMed ID: 28108509
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
4. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
5. Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ.
Uehara M; McGrath MM; Ohori S; Solhjou Z; Banouni N; Routray S; Evans C; DiNitto JP; Elkhal A; Turka LA; Strom TB; Tullius SG; Winkler DG; Azzi J; Abdi R
Nat Commun; 2017 Oct; 8(1):951. PubMed ID: 29038423
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
Suárez-Fueyo A; Rojas JM; Cariaga AE; García E; Steiner BH; Barber DF; Puri KD; Carrera AC
J Immunol; 2014 Jul; 193(2):544-54. PubMed ID: 24935930
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.
Abu-Eid R; Samara RN; Ozbun L; Abdalla MY; Berzofsky JA; Friedman KM; Mkrtichyan M; Khleif SN
Cancer Immunol Res; 2014 Nov; 2(11):1080-9. PubMed ID: 25080445
[TBL] [Abstract][Full Text] [Related]
11. Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Stark AK; Davenport ECM; Patton DT; Scudamore CL; Vanhaesebroeck B; Veldhoen M; Garden OA; Okkenhaug K
J Immunol; 2020 Jul; 205(1):78-89. PubMed ID: 32414808
[TBL] [Abstract][Full Text] [Related]
12. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
13. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
Alderson KL; Zhou Q; Berner V; Wilkins DE; Weiss JM; Blazar BR; Welniak LA; Wiltrout RH; Redelman D; Murphy WJ
J Immunol; 2008 Mar; 180(5):2981-8. PubMed ID: 18292520
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Acid Sphingomyelinase Allows for Selective Targeting of CD4+ Conventional versus Foxp3+ Regulatory T Cells.
Hollmann C; Werner S; Avota E; Reuter D; Japtok L; Kleuser B; Gulbins E; Becker KA; Schneider-Schaulies J; Beyersdorf N
J Immunol; 2016 Oct; 197(8):3130-3141. PubMed ID: 27638864
[TBL] [Abstract][Full Text] [Related]
15. A Novel mTORC1-Dependent, Akt-Independent Pathway Differentiates the Gut Tropism of Regulatory and Conventional CD4 T Cells.
Chen LC; Nicholson YT; Rosborough BR; Thomson AW; Raimondi G
J Immunol; 2016 Aug; 197(4):1137-47. PubMed ID: 27402696
[TBL] [Abstract][Full Text] [Related]
16. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4
Binnewies M; Mujal AM; Pollack JL; Combes AJ; Hardison EA; Barry KC; Tsui J; Ruhland MK; Kersten K; Abushawish MA; Spasic M; Giurintano JP; Chan V; Daud AI; Ha P; Ye CJ; Roberts EW; Krummel MF
Cell; 2019 Apr; 177(3):556-571.e16. PubMed ID: 30955881
[TBL] [Abstract][Full Text] [Related]
17. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF
Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
[TBL] [Abstract][Full Text] [Related]
18. 2,3,7,8-Tetrachlorodibenzo-p-dioxin alters the differentiation of alloreactive CD8+ T cells toward a regulatory T cell phenotype by a mechanism that is dependent on aryl hydrocarbon receptor in CD4+ T cells.
Funatake CJ; Marshall NB; Kerkvliet NI
J Immunotoxicol; 2008 Jan; 5(1):81-91. PubMed ID: 18382861
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
20. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
